Objective

To evaluate the predictive value of a single nucleotide polymorphism (SNP) rs2686344 and squamous cell carcinoma antigen (SCCAg) levels in the clinical efficacy of neoadjuvant chemotherapy (NACT) for cervical cancer.

Methods

A total of 92 patients with stage IB2-IIIB carcinoma of the uterine cervix who received NACT treatment were enrolled. The relationship between the genotypes of SNP rs2686344 which is located on CAMKK2 on chromosome 12, SCCAg levels and the response to NACT was analyzed. The relationship between the SNP rs2686344 genotypes, SCCAg levels, the response to NACT and the five-year survival rate was evaluated.

Results

The effective group accounted for 84.85% in patients with low level (≤3.5 ng/mL) of post-treatment SCCAg (post-SCCAg), while the ineffective group accounted for 15.15%. The post-SCCAg levels and the genotypes of rs2686344 were significantly correlated with NACT response (P = 0.003, and P = 0.006). In patients with CC or CT genotype of SNP rs2686344, effective group accounted for 81.18%, while ineffective group accounted for 18.82%; For patients with TT genotype, effective response group accounted for 28.57%, ineffective group accounted for 71.43%. Post-SCCAg level >3.5 ng/mL and TT genotype of SNP rs2686344 showed as independent risk factors for NACT response in the multivariate analysis (P = 0.002, and P = 0.048). There was no significant difference in 5-year overall survival and 5-year disease-free survival between patients with different levels of post-SCCAg, or among different rs2686344 genotypes.

Conclusion

The high level of post-SCCAg (>3.5 ng/mL) and TT genotype of rs2686344 may suggest a higher risk of poor response to NACT.

中文翻译：

---

Rs2686344和血清鳞状细胞癌抗原可预测宫颈癌新辅助化疗的临床疗效

客观的

评估单核苷酸多态性 (SNP) rs2686344 和鳞状细胞癌抗原 (SCCAg) 水平对宫颈癌新辅助化疗 (NACT) 临床疗效的预测价值。

方法

共纳入 92 例接受 NACT 治疗的 IB2-IIIB 期宫颈癌患者。分析了位于12号染色体CAMKK2上的SNP rs2686344基因型、SCCAg水平和对NACT反应的关系。评估了 SNP rs2686344 基因型、SCCAg 水平、对 NACT 的反应和五年生存率之间的关系。

结果

治疗后SCCAg（post-SCCAg）水平低（≤3.5 ng/mL）的患者有效组占84.85%，无效组占15.15%。SCCAg 后水平和 rs2686344 基因型与 NACT 反应显着相关（P  = 0.003 和P  = 0.006）。在CC或CT基因型SNP rs2686344的患者中，有效组占81.18%，无效组占18.82%；对于TT基因型患者，有效反应组占28.57%，无效组占71.43%。在多变量分析中，SCCAg 后水平 >3.5 ng/mL 和 SNP rs2686344 的 TT 基因型显示为 NACT 反应的独立危险因素（P  = 0.002 和P = 0.048）。不同水平的 SCCAg 后患者或不同 rs2686344 基因型之间的 5 年总生存率和 5 年无病生存率没​​有显着差异。

结论

rs2686344 的高水平后 SCCAg (>3.5 ng/mL) 和 TT 基因型可能表明对 NACT 反应不佳的风险更高。